PaulWSpearmanMD

Pediatric Infectious Disease • Cincinnati, OH

Albert B. Sabin Professor and Director, Infectious Diseases, Cincinnati Children's Hospital

Join to view full profile

Dr. Spearman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Spearman's full profile

Already have an account?

Office
3333 Burnet Ave
# ML7017
Cincinnati, OH 45229
Phone+1 513-636-4578

Fax+1 513-636-7039

Summary

Paul Spearman, MD is the Albert B. Sabin Professor and Director of Infectious Diseases at Cincinnati Children’s Hospital Medical Center. His laboratory studies fundamental aspects of HIV biology and develops new vaccines for human pathogens. HIV assembly processes are a major focus of the laboratory, including the trafficking of the HIV envelope glycoprotein and its interaction with essential host factors. A related project studies how HIV interacts with macrophages and microglia. Dr. Spearman and his colleagues in the CCHMC Vaccine and Treatment Evaluation Unit (VTEU) are engaged in the design and performance of clinical trials for new vaccines in adults and children, with a special interest in employing cutting-edge technologies to define innate and adaptive immune responses to vaccines. Dr. Spearman is currently leading trials for Ebola and RSV vaccine development.

Dr. Spearman serves on the Board of Scientific Counselors for NCI, the Vaccines and Related Biological Products Advisory Committee for the FDA, and is Past President of the Pediatric Infectious Diseases Society (PIDS). Beyond his research interests, Dr. Spearman is a Pediatric ID clinician and enjoys caring for children and mentoring future leaders in Infectious Diseases.

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 1990 - 1994
Ohio State University HospitalResidency, Internal Medicine, 1986 - 1990
University of Texas Southwestern Medical SchoolClass of 1986

Certifications & Licensure

OH State Medical License 1987 - 2026
IN State Medical License 2021 - 2025
KY State Medical License 2021 - 2024
GA State Medical License 2005 - 2017
TN State Medical License 1994 - 2007
American Board of Internal Medicine Infectious Disease
American Board of Pediatrics Pediatric Infectious Diseases

Awards, Honors, & Recognition

Fellow, Pediatric Infectious Diseases Society (FPIDS) Pediatric Infectious Diseases Society
Fellow, Infectious Diseases Society of America (FIDSA) Infectious Diseases Society of America
Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
Completed
Phase 1
Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
Completed
Phase 1
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP Start of enrollment: 2004 Apr 01
Completed
Phase 1
Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials Start of enrollment: 2011 Jul 01
Completed
Phase 1
Antibiotic Safety (SCAMP) Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

173 citations
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans
Ali H. Ellebedy, Florian Krammer, Gui-Mei Li, Matthew S. Miller, Christopher Chiu
Proceedings of the National Academy of Sciences of the United States of America. 2014-09-09
78 citations
Rab11-FIP1C and Rab14 Direct Plasma Membrane Sorting and Particle Incorporation of the HIV-1 Envelope Glycoprotein Complex
Mingli Qi, Janice A. Williams, Hin Chu, Xuemin Chen, Jaang Jiun Wang
Plos Pathogens. 2013-04-04
38 citations
Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.
Jason Hammonds, Xuemin Chen, Lingmei Ding, Timothy R. Fouts, Anthony De Vico
Virology. 2003-09-30

Press Mentions

HIV Status Has No Place in Border Patrol PolicyJuly 29th, 2019
Possible Link Between Virus and Acute Flaccid Myelitis, the 'Polio-Like' DiseaseApril 29th, 2019
US Researchers Look for Long-Lasting Ebola VaccineFebruary 1st, 2019
Join now to see all

Grant Support

Role Of Vpu In Retroviral Particle AssemblyNational Institute Of Allergy And Infectious Diseases2006–2012
Viral And Cellullar Determinants Of HIV-1 AssemblyNational Institute Of Allergy And Infectious Diseases2010
Defining Neutralization Breadth In HIV+ Human SerumNational Institute Of Allergy And Infectious Diseases2009–2010
Virology CoreNational Institute Of Allergy And Infectious Diseases2006–2010
FEI Transmission Electron Microscope With Tomography CapabilityNational Center For Research Resources2009
Viral And Cellular Determinants Of HIV-1 AssemblyNational Institute Of Allergy And Infectious Diseases2005–2009
Pseudovirion Formation By Live Vector HIV VaccinesNational Institute Of Allergy And Infectious Diseases2006–2007
Novel Assays For Inhibitors Of HIV AssemblyNational Institute Of Allergy And Infectious Diseases2005–2007
Development Of Enhanced HIV-1 Pseudovirion VaccinesNational Institute Of Allergy And Infectious Diseases2005–2006
Normal Volunteer Blood DonationNational Center For Research Resources2005–2006
A Probe Study Of The Safety, Tolerability, And Immunogenicity Of Human ImmunoNational Center For Research Resources2005–2006
A Probe Study Of The Safety, Tolerability And Immunogenicity Of A Three-DoseNational Center For Research Resources2005–2006
A Phase I Safety And Immunogenicity Trial Of An Alphavirus Replicon HIV SubtyNational Center For Research Resources2005–2006
Novel Assays For Inhibitors Of HIV AssemblyNational Institute Of Allergy And Infectious Diseases2005
A Phase I Dose-Ranging Study Of The Safety, Tolerability, And ImmunogencityNational Center For Research Resources2005
Role Of Vpu In Retroviral Particle AssemblyNational Institute Of Allergy And Infectious Diseases2004–2005
Development Of Pooled HIV Positive SERA For Basic Investigations Into HIV BIONational Center For Research Resources2004–2005
Development Of Enhanced HIV-1 Pseudovirion VaccinesNational Institute Of Allergy And Infectious Diseases2002–2005
Viral And Cellular Determinants Of HIV-1 AssemblyNational Institute Of Allergy And Infectious Diseases2001–2005
Normal Volunteer Blood Donation .National Center For Research Resources2004
A Probe Study Of The Safety, Tolerability And Immunogenicity Of A Three-Dose...National Center For Research Resources2004
A Phase I Safety And Immunogenicity Trial Of An Alphavirus Replicon HIV Subty...National Center For Research Resources2004
Novel Fret-Based Assays For HIV Assembly InhibitorsNational Institute Of Allergy And Infectious Diseases2003–2004
Membrane Binding And Transport Of HIV1 PR55National Institute Of Allergy And Infectious Diseases1997–2001
Induction Of KSHV Replication By HIV 1National Cancer Institute2000
Development Of Enhanced HIV 1 Pseudovirion VaccinesNational Institute Of Allergy And Infectious Diseases1999–2000